Contact Us
Drug Search Results
More Filters [+]

Paritaprevir

Alternative Names: paritaprevir, abt-450, viekira xr, technivie, viekira pak (copackaged), viekira pak
Latest Update: 2024-08-23
Latest Update Note: Clinical Trial Update

Product Description

Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Paritaprevir)

Mechanisms of Action: HCV-NS3/4A Inhibitor,SP

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States | Venezuela

Approved Indications: Liver Cirrhosis | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic | Liver Cirrhosis | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic

Known Adverse Events: Insomnia | Pruritus | Asthenia | Headache Disorders | Dizziness | Headache | Pain Unspecified | Liver Cirrhosis | Musculoskeletal Pain | Dyspnea

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Paritaprevir

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Hepatitis C, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2015-000111-41

P3

Completed

Hepatitis C, Chronic

2023-05-01

Recent News Events

Date

Type

Title

06/13/2023

News Article

 Hepatitis C Market is Expected to Drive Growth at 14.2% By 2032

02/08/2023

News Article

 Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.

08/23/2021

News Article

 TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

07/20/2021

News Article

 U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions